27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
US biotech major Amgen rolled out senior executives and a swish presentation in providing an update on two of its drugs in Phase III trials this week. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
German drug discovery company Evotec has entered a technology development partnership with Danish drugmaker Novo Nordisk in cell therapy. 26 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
LEO Pharma has presented late-breaking data on the DELTA FORCE trial for Anzupgo (delgocitinib) cream as a potential treatment for adult patients with moderate to severe chronic hand eczema (CHE). 26 September 2024
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Joenja (leniolisib), from Netherlands-based Pharming. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Shanghai-based Junshi Biosciences has announced that the European Commission has approved Loqtorzi (toripalimab) for two cancer indications. 26 September 2024
Asklepios BioPharmaceutical (AskBio), a gene therapy company wholly-owned and independently operated as a subsidiary of Bayer, has announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. 25 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Privately-held Icelandic biosimilars developer Alvotech Holdings says it has executed a US settlement agreement with AbbVie that grants Alvotech non-exclusive rights to market AVT02 (100mg/mL), its high-concentration, citrate-free biosimilar candidate for Humira (adalimumab) in the USA 9 March 2022
California, USA-based clinical-stage biotech CODA Biotherapeutics, which is focussed on neurological disorders, has appointed Susan Catalano as chief scientific officer. 9 March 2022
French vaccines developer Valneva announced the successful completion of the Phase III pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. 9 March 2022
Confirming that BioNTech is not just a one trick pony - having been behind the discovery of the most successful COIVD-19 vaccines, the German biotech today announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). 8 March 2022
The life sciences division of tech major NEC Corporation has bought immuno-oncology assets from Swiss-German biotech Vaximm, for an undisclosed amount. 8 March 2022
Private UK-based cell and gene therapy company Ixaka, previously known as Rexgenero, has announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted by the European Medicines Agency (EMA) for its Chemically Encapsulated Lentiviral vector for Targeted In Vivo CAR T-cell therapy (CELTIC-19) targeted nanoparticle (TNP) product. 8 March 2022
Pharmaceutical companies and vaccine makers in India who have developed potential vaccine candidates against dengue are in for some good times, with the Indian Council of Medical Research (ICMR) inviting domestic pharma companies to collaborate on the development of the country’s first vaccine for dengue. 8 March 2022
German CNS specialist Neuraxpharm Group today announced the expansion of its business in Southeast Europe through the acquisition of Greece-headquartered Brain Therapeutics, a CNS-focused marketing and distribution company with longstanding expertise in commercialization of CNS products in Greece, Cyprus and the Balkan countries. 8 March 2022
Belgium’s largest drugmaker, UCB , today announced it will build an innovative and environmentally sustainable gene therapy process development and clinical manufacturing facility on their high-tech campus in Braine l’Alleud, Wallonia, Belgium. 8 March 2022
The US subsidiary of Israeli generic giant Teva Pharmaceutical Industries has announced the launch of a first generic version of Revlimid (lenalidomide capsules), in 5mg, 10mg, 15mg, and 25mg strengths, in the USA. 8 March 2022
In London, the Global Pandemic Preparedness Summit is bringing together new sources of funding while aiming to boost cooperation between countries and healthcare organizations in the face of possible future threats. 8 March 2022
A partial clinical hold on Alpine Immune Sciences' NEON-2 trial has taken a bite out of the firm’s share price, with stocks falling 9% on Monday. 8 March 2022
Following the filing of a Citizen Petition last Friday by French drug major Sanofi calling on the US Food and Drug Administration to review the labels for influenza vaccines from Seqirus, a subsidiary of Australia’s CSL Limited, Seqirus has issued its own view. 8 March 2022
US biotech major Gilead Sciences’ shares fell as much as 5% yesterday, after it announced results from the Phase III TROPiCS-02 study evaluating Trodelvy (sacituzumab govitecan-hziy) in patients with HR+/HER2- metastatic breast cancer who received prior endocrine therapy, CDK4/6 inhibitors and two to four lines of chemotherapy. 8 March 2022
The US Food and Drug Administration yesterday published a funding opportunity announcement (FOA) to support research projects that enhance biosimilar and interchangeable biological product development and regulatory science. 8 March 2022
US mRNA therapeutics and vaccines developer Moderna today announced that, with the assistance of the US government, it has entered into a Memorandum of Understanding with the government of Kenya to establish Kenya as the location for the company's mRNA manufacturing facility. 7 March 2022
Midway through its annual report, Massachusetts-based gene therapy company bluebird bio (Nasdaq: BLUE) made the startling admission that it’s running out of cash, fast. 7 March 2022
Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) has been granted a marketing authorization by the European Commission (EC) for the treatment of adults with symptomatic chronic heart failure. 7 March 2022